


## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

**Mail Stop: PCT**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on April 28, 2006.  
Date

  
Signature

Diane Payne  
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

**Applicant: Erik De Vries, *et al.***  
**Serial No: 10/571,667**  
**Title: Piroplasmid Vaccine**  
**International Filing Date: September 14, 2004**  
**Customer No.: 31846**  
**Attorney Docket: I-2003.010 US**

Receipt acknowledged of the following documents in the above-identified application:

Information Disclosure Statement (2 pages)  
PTO Form SB 08B (1 page)  
Cited Reference (1 ref.) (13 pages)  
Self-addressed stamped post card (1)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No: 10/571,667  
Applicant: Erik De Vries, et al.  
Confirmation No: 2304  
International Filing date: September 14, 2004  
Group Art Unit: TBA  
Examiner: TBA  
For: Piroplasmid Vaccine  
Attorney Docket: I-2003.010 US  
Corresponding to: National Phase Entry Under 35 U.S.C. § 371 of  
PCT/EP2004/052169, filed September 14, 2004

April 28, 2006

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 CFR 1.97(b)**

**Mail Stop: PCT**  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir/Madam:

The attention of the Patent and Trademark Office is hereby directed to the document listed on the attached Form PTO-SB-08B. A copy of the cited reference is enclosed.

Applicants reserve the right to show that the cited document was not actually published on the date or month or year indicated. Applicants also reserve the right to argue that the cited document does not constitute prior art under, *inter alia*, 35 U.S.C. sections 102 or 103.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

Applicants do not believe that any other fee is due in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. 02-2334. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. 02-2334.

Applicants submit that this application is in condition for allowance, and request that it be allowed. The Examiner is requested to call the Undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,



Aaron L. Schwartz, PTO Reg. No. 48,181  
Patent Counsel

Intervet Inc.  
Patent Department  
P.O. Box 318  
29160 Intervet Lane  
Millsboro, DE 19966  
(302) 933-4034 (tel)  
(302) 934-4305 (fax)

ALS:dap

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/571,667
		Filing Date (Int'l)	September 14, 2004
		First Named Inventor	Erik De Vries, et al.
		Art Unit	To be assigned
		Examiner Name	To be assigned
Sheet 1	of 1	Attorney Docket Number	I-2003.010 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		De Vries, E. et al., "Analysis of Proteins Involved in Erythrocyte Invasion by Babesia Bovis", poster presented at Woodshole Conference, August 2003.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.